The National Rare Cardiac Engagement & Evidence Insights Lead plays a mission‑critical role in sustaining and advancing Pfizer’s leadership in the evolving Rare Cardiac and Amyloid landscape and informs broader enterprise strategy and future rare cardiac and amyloid business development opportunities. As Vyndamax — now a $4B focus brand for Pfizer — enters its second year of an intense and pivotal competitive period, this role is central to shaping the national amyloid growth strategy by translating deep HCP insights into clinical data positioning, and enterprise‑wide execution across the most impactful accounts. We are also entering a critical midlife cycle planning phase which requires continued pulse and focus on the rare cardiac space. This role serves as the connective tissue between HCP mindset, clinical evidence, and commercial strategy, ensuring that promotion is directly informed by real‑world insights from priority physicians and institutions. Success in this role accelerates share growth by aligning stakeholders around a unified strategy in the Top 25 amyloid accounts that disproportionately influence business performance. Acting as a strategic bridge between HQ and field teams, this decision‑shaping leadership role will determine which insights matter, how they can support evidence, and where the organization focuses to win. Through insight-driven decision-making and continuous optimization, this role helps maintain commercial momentum and leadership of Vyndamax in a dynamic ATTR-CM market. Beyond Amyloid/Vyndamax execution, this role functions as the enterprise‑level point of integration for external amyloid insights, rare cardiac market place insights serving as a strategic input into future business development considerations and ensuring market learnings inform broader enterprise strategy.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior